SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of results from preclinical studies of CAL-120, a novel oral beta/delta PI3K inhibitor, at the AACR-EORTC-NCI International Molecular Targets and Cancer Therapeutics Conference in Boston, Mass.
